• 1
    De Mulder PH, Van Herpen CM, Mulders PA. Current treatment of renal cell carcinoma. Ann Oncol 2004; 15: 31928
  • 2
    Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 4818
  • 3
    Jemal A, Siegel R, Ward E et al. Cancer statistics 2006. CA Cancer J Clin 2006; 56: 10630
  • 4
    Reis LAG, Harkins D, Krapcho M et al. Seer Cancer Statistics Review, 1975–2003. National Cancer Institute, 2007. Available at: Based on November 2005 SEER data submission, posted to the SEER website. Accessed 15 February 2007
  • 5
    Gleave ME, Elhilali M, Fradet Y et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 1998; 338: 126571
  • 6
    Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol 1992; 148: 12478
  • 7
    Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 40817
  • 8
    Kirkwood JM, Harris JE, Vera R et al. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res 1985; 45: 86371
  • 9
    Kriegmair M, Oberneder R, Hofstetter A. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 1995; 45: 75862
  • 10
    Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17: 285967
  • 11
    Steineck G, Strander H, Carbin BE et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol 1990; 29: 15562
  • 12
    Coppin C, Porzsolt F, Awa A et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; 1: CD001425
  • 13
    Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999; 353: 147
  • 14
    Motzer RJ, Bacik J, Murphy BA et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 28996
  • 15
    Fossa SD, Martinelli G, Otto U et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol 1992; 3: 3015
  • 16
    Kinouchi T, Sakamoto J, Tsukamoto T et al. Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis. J Cancer Res Clin Oncol 2006; 132: 499504
  • 17
    Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med 1998; 338: 12728
  • 18
    Sagaster P, Micksche M, Flamm J, Ludwig H. Randomised study using IFN-alpha versus IFN-alpha plus coumarin and cimetidine for treatment of advanced renal cell cancer. Ann Oncol 1995; 6: 9991003
  • 19
    Aass N, De Mulder PH, Mickisch GH et al. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol 2005; 23: 41728
  • 20
    Atzpodien J, Kirchner H, Illiger HJ et al. IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001; 85: 11306
  • 21
    Infergen: Summary of product characteristics. Available at: Accessed 16 November 2006
  • 22
    Proleukin. Summary of product characteristics. Available at: Accessed 17 November 2006
  • 23
    National Comprehensive Guidelines Network. Kidney cancer. Available at: Accessed 15 June 2007
  • 24
    Halbert RJ, Figlin RA, Atkins MB et al. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer 2006; 107: 237583
  • 25
    Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 148592
  • 26
    Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004; 10: 6342S6S
  • 27
    Spanknebel K, Cheung KY, Stoutenburg J et al. Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2. Ann Surg Oncol 2005; 12: 38190
  • 28
    Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6: S557
  • 29
    Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13: 68896
  • 30
    McDermott DF, Regan MM, Clark JI et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 13341
  • 31
    Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21: 312732
  • 32
    Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998; 228: 30719
  • 33
    Dutcher JP. Is high-dose interleukin-2 the treatment of choice for metastatic renal carcinoma? Kidney Cancer J 2003; 1: 512
  • 34
    Negrier S. Cytokines in metastatic renal cell carcinoma: conclusions from the French PERCY program. Ann Oncol 2006; 17: 25IN Abstract
  • 35
    Figlin R, Gitlitz B, Franklin J et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am 1997; 3: S927
  • 36
    Motzer RJ. Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma. Crit Rev Oncol Hematol 2003; 46: S339
  • 37
    Negrier S, Gomez F, Douillard JY et al. Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. World J Urol 2005; 23: 1615
  • 38
    Padrik P. Prognostic factors of immunotherapy in metastatic renal cell carcinoma. Med Oncol 2003; 20: 32534
  • 39
    Upton MP, Parker RA, Youmans A et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005; 28: 48895
  • 40
    Motzer RJ, Bacik J, Mariani T et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20: 237681
  • 41
    Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9: 80211
  • 42
    Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11: 371421
  • 43
    Hutson TE, Quinn DI. Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Clin Genitourin Cancer 2005; 4: 1816
  • 44
    Cesana GC, DeRaffele G, Cohen S et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24: 116977
  • 45
    Donskov F, Von Der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 19972005
  • 46
    Anonymous. Roferon-α (IFN-α-2α, recombinant). Prescribing information. Available at: Accessed 15 February 2007
  • 47
    Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 12534
  • 48
    Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 11524
  • 49
    Hudes G, Carducci M, Tomczac P et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006; 24: Lba4 (Abstract)
  • 50
    Escudier B, Koralewski P, Pluzanska A et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 2007; 25: 3 (Abstract)
  • 51
    Dhanda R, Gondek K, Song J et al. A quality of life, symptoms and survival comparison in kidney cancer patients receiving sorafenib versus placebo. Ann Oncol 2006; 17: 447PD (Abstract)
  • 52
    Szczylik C, Demkow T, Staehler M et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 2007; 25: 5025 (Abstract)
  • 53
    Ryan CW, Bukowski RM, Figlin RA et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: long-term outcomes in first-line patients (pts). J Clin Oncol 2007; 25: 5096 (Abstract)
  • 54
    Jonasch E, Corn P, Ashe RG, Do K, Tannir NM. Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. J Clin Oncol 2007; 25: 5104 (Abstract)